Please login to the form below

Not currently logged in

ocular gene therapy

This page shows the latest ocular gene therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis to pay up to $1.5bn for Gyroscope

Novartis to pay up to $1.5bn for Gyroscope

The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness. ... Gyroscope is a clinical-stage gene therapy company working on eye

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary ... team. Chris Hollowood, chairman of the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story